Table 5 Number of quality assessment criteria addressed by individual studies
Journal articles | |||||||||
| Â | Batty AJ, et al | Giannouchos TV, et al | Hansson-Hedblom A, et al | Hollier-Hann G, et al | Lipton RB, et al | Mahon R, et al | Ruggeri, et al. | Sussman M, et al | Vekov, et al |
CHEERS 2022 (n = 28) | |||||||||
 Yes | 25 | 23 | 23 | 23 | 22 | 25 | 23 | 25 | 12 |
 No | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 10 |
 Partial | 1 | 3 | 3 | 2 | 4 | 1 | 3 | 1 | 6 |
 Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHILIPS CRITERIA (n = 57) | |||||||||
 Yes | 51 | 50 | 50 | 49 | 51 | 51 | 50 | 51 | 20 |
 No | 3 | 4 | 4 | 6 | 4 | 3 | 3 | 3 | 16 |
 Partial | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 9 |
 Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 10 |
 Not applicable | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 |
Other reports | |||||||||
| Â | CADTH (Botox) | CADTH (Erenumab) | ICER | NICE (Erenumab) | NICE (Fremanezumab) | NICE (Galcenzenumab) | Warwick Evidence (Botox) | Â | |
CHEERS 2022 (n = 27) | |||||||||
 Yes | 27 | 26 | 25 | 27 | 27 | 27 | 24 |  | |
 No | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | |
 Partial | 0 | 1 | 2 | 0 | 0 | 0 | 3 |  | |
 Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  | |
 Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  | |
PHILIPS CRITERIA (n = 57) | |||||||||
 Yes | 50 | 49 | 52 | 53 | 54 | 55 | 55 |  | |
 No | 3 | 2 | 1 | 2 | 1 | 0 | 0 |  | |
 Partial | 4 | 6 | 4 | 1 | 1 | 1 | 2 |  | |
 Unclear | 0 | 0 | 0 | 1 | 1 | 1 | 0 |  | |
 Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  | |